Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Table 1 Summary of clinical trial results of monoclonal antibody-based therapies

Study	Target disease	No. of patients	Objective response rate	Complete response rate	Median progression-free survival	Overall survival	Adverse events or other subjects	Ref.
Tafasitamab plus lenalidomide phase-II L-MID	r/r DLBCL (no FL) > 35 mo follow up	n = 80	57.5% (n = 46/80)	40.0% (n = 32/80)	11.6 mo	33.5 mo	No unexpected toxicity	[14]
Phase-II ROMULUS, rituximab-polatuzumab vs rituximab-pinatuzumab	r/r FL	n = 42, n = 20, n = 21	70% (n = 14/20); 62% (n = 13/21)	45% (n = 9/20); 5% (n = 1/21)	Unknown	Unknown		[15]
Loncastuximab tesirine (ADTC-402) frontline therapy	Untreated FL	Total, DLBCL, MZL, FL	45.6%, 42.3%, 46.7%, 78.6%	26.7%	Unknown	Unknown	Median duration response: 5.4 mo	[16]
Magrolimab plus rituximab phase-Ib	r/r DLBCL; r/r FL	n = 22; DLBCL:15; FL: 7	50% (CR or PR); 40%, 71% (n = 5/7)	33%, 43% (n = 3/7)	Unknown	Unknown	90% response were on going, a median follow-up of 6.2 (DLBCL)/8.1 (FL) mo	[17]
Venetoclax plus obinutumab phase-I	Untreated FL	CT, PET/CT	87.5%, 84.2%	25.0%, 68.4%	77.8% (at one yr); 79.0% (at one yr); 73.2% (at 30 mo); 79.0% (at 30 mo)	Unknown; unknown		[19]
GALLIUM trial obinutuzumab + CTx rituximab + CTx	Untreated FL	n = 1202, n = 601, n = 601	88.5%, 86.9%	Unknown, unknown	80.0% (at 3 yr); 73.3% (at 3 yr)	Unknown, unknown	Obinutuzumab is better	[20,21]

“Unknown” means data not shown, unknown information or not reached. r/r: Refractory and relapsed; FL: Follicular lymphoma; DLBCL: Diffuse large B-cell lymphoma; MZL: Marginal zone lymphoma; (R-)CHOP: (Rituximab plus) cyclophosphamide, doxorubicin, vincristine, and prednisolone; CT: Computed tomography; PET/CT: Positron emission tomography/computed tomography; CTx: Traditional chemotherapy.